Soybean Aphid Biotype 4 Resistance in Soja and Soybean Plant Introductions

Soybean aphid, Aphis glycines Matsumura, is a major pest to soybean, Glycine max (L.) Merr. Host plant resistance is a management tactic that uses naturally occurring soybean plant defenses to limit soybean aphid pest damage. Virulent soybean aphid biotypes are able to successfully colonize on certain aphid resistant soybean. Soybean aphid biotype 4 is most virulent, overcoming all commercially available soybean aphid resistant soybeans (Rag1, Rag2, and Rag1+Rag2). Additional sources of resistance to avirulent biotypes have been identified in soja and soybean plant introductions (PIs). This study examined those resistant soja and soybean for resistance to the newly found soybean aphid biotype 4, using iso-female colonies of soybean aphid from three different site-years. Free-choice tests examined 20 soja and 50 soybean PIs for putative resistance to the three soybean aphid biotype 4 colonies. Promising PIs continued on in a follow-up, caged no-choice test with its respective colony. Soja PI 65549 and PI 101404A and soybean PI 437696 were found highly resistant to each of the three soybean aphid biotype 4 colonies and should be explored further as valuable sources of soybean aphid resistance

Clarification on the generation of absolute and potential vorticity in mesoscale convective vortices

Atmos. Chem. Phys., 9, 7591-760

Mesoscale convective vortex formation in a weakly sheared moist neutral environment

J. Atmos. Sci., 64, 1443-1466The article of record as published may be located at http://dx.doi.org/10.1175/JAS3898.

The use of imepitoin (Pexion™) on fear and anxiety related problems in dogs – a case series

Fear and anxiety based problems are common in dogs. Alongside behaviour modification programmes, a range of psychopharmacological agents may be recommended to treat such problems, but few are licensed for use in dogs and the onset of action of some can be delayed. The low affinity partial benzodiazepine receptor agonist imepitoin (Pexion™, Boehringer Ingelheim) is licensed for treating canine epilepsy, has a fast onset of action in dogs and has demonstrated anxiolytic properties in rodent models. This case series reports on the use of imepitoin in a group of dogs identified as having fear/anxiety based problems. Twenty dogs were enrolled into the study, attended a behaviour consultation and underwent routine laboratory evaluation. Nineteen dogs proceeded to be treated with imepitoin orally twice daily (starting dose approximately 10 mg/kg, with alterations as required to a maximum 30 mg/kg) alongside a patient-specific behaviour modification plan for a period of 11–19 weeks. Progress was monitored via owner report through daily diary entries and telephone follow-up every two weeks. A Positive and Negative Activation Scale (PANAS) of temperament was also completed by owners during baseline and at the end of the study

Analgesic management of an eight-year-old Springer Spaniel after amputation of a thoracic limb

Analgesic agents were administered perioperatively to an eight-year-old Springer Spaniel undergoing amputation of its right thoracic limb. The amputation was carried out due to a painful, infiltrative and poorly differentiated sarcoma involving the nerves of the brachial plexus. A combination of pre-emptive and multimodal perioperative analgesic strategies was used; including intravenous (IV) infusions of fentanyl, morphine, lidocaine and ketamine